Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bridgebio Pharma Inc
(NQ:
BBIO
)
29.50
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Bridgebio Pharma Inc
< Previous
1
2
3
4
5
6
7
Next >
12 Health Care Stocks Moving In Monday's Pre-Market Session
November 25, 2024
Via
Benzinga
Gold Down Over 3%; Rigetti Computing Shares Spike Higher
November 25, 2024
Via
Benzinga
Crude Oil Down 3%; Chicago Fed National Activity Index Falls In October
November 25, 2024
Via
Benzinga
Topics
Economy
Exposures
Fossil Fuels
Interest Rates
BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday
November 25, 2024
Via
Benzinga
Why BridgeBio Pharma Stock Is Trading Lower Tuesday
June 04, 2024
BridgeBio Pharma, Inc.
Via
Benzinga
Recap: BridgeBio Pharma Q4 Earnings
February 22, 2024
Via
Benzinga
BridgeBio Catapults After Snagging Approval For Pfizer-Rivaling Heart Drug
November 25, 2024
BridgeBio will sell its drug at a slightly lower wholesale acquisition cost compared to Pfizer's blockbuster, Vyndaqel.
Via
Investor's Business Daily
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
November 25, 2024
FDA approves BridgeBio's Attruby for ATTR-CM. Phase 3 results highlight its effectiveness in reducing cardiovascular risks and improving life quality.
Via
Benzinga
Exposures
Product Safety
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
November 19, 2024
BridgeBio's acoramidis shows significant reductions in mortality and hospitalizations in ATTR-CM patients, with no new safety concerns in long-term studies.
Via
Benzinga
3 Top Stocks That Could Still Rocket Higher in 2024
October 04, 2024
Upcoming Food and Drug Administration decisions could push these stocks through the roof.
Via
The Motley Fool
BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease
September 30, 2024
BridgeBio Pharma shared new data showing that acoramidis reduced mortality and cardiovascular hospitalizations by 42% in its Phase 3 ATTRibute-CM study for ATTR-CM. FDA decision expected in November...
Via
Benzinga
Exposures
Product Safety
BridgeBio Pharma Seeks Partner To Develop Gene Therapy For Inherited Condition
September 11, 2024
BridgeBio Pharma released Phase 1/2 trial results for BBP-631, its gene therapy for congenital adrenal hyperplasia. The study demonstrated increased cortisol production and reductions in key...
Via
Benzinga
Patchy And Still Patchy In The Short Term
September 09, 2024
In the very short term, I would say the further downside is likely but not for long. These are not ideal conditions, so either sit it out or make sure you take your profits early.
Via
Talk Markets
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
September 03, 2024
Via
Benzinga
Why Is BridgeBio Pharma Stock Trading Higher On Friday?
August 30, 2024
BridgeBio Pharma presented additional data from its Phase 3 ATTRibute-CM study of acoramidis in ATTR-CM at the European Society of Cardiology 2024, showing increased serum TTR levels in participants...
Via
Benzinga
Marvell Technology Posts Upbeat Sales, Joins MongoDB, Intel, MINISO Group And Other Big Stocks Moving Higher On Friday
August 30, 2024
Via
Benzinga
Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart Muscles
August 30, 2024
Alnylam Pharmaceuticals shares drop as detailed results from the HELIOS-B Phase 3 study of vutrisiran for ATTR-CM reveal mixed outcomes. Reductions in mortality and cardiovascular events were presented...
Via
Benzinga
BBIO Stock Earnings: BridgeBio Pharma Misses EPS, Misses Revenue for Q2 2024
August 01, 2024
BBIO stock results show that BridgeBio Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Via
InvestorPlace
ResMed, Coinbase Global, Nvidia And Other Big Stocks Moving Lower On Monday
June 24, 2024
Via
Benzinga
Masters In Trading - Saturday, June 22
June 22, 2024
In this video, I discuss a stock that is expected to see major upside, and I take a closer look at my portfolio.
Via
Talk Markets
The 3 Best Biotech Stocks to Buy in June 2024
June 05, 2024
Explore the best biotech stocks to buy in June 2024, with insights on Protagonist, BridgeBio and Intellia.
Via
InvestorPlace
BridgeBio Pharma Shares One Year Data From Dwarfism Candidate
June 04, 2024
BridgeBio Pharma revealed results from the PROPEL 2 Phase 2 trial of infigratinib in children with achondroplasia. Key data shows sustained increases in height velocity and improved body...
Via
Benzinga
BridgeBio Stock Makes A Bullish Move On Dwarfism Treatment Results
June 04, 2024
BridgeBio stock rallies on upbeat study results of a drug for a genetic disease that affects the limbs and spine.
Via
Investor's Business Daily
7 Biotech Stocks to Put on Your Breakthrough Radar
May 27, 2024
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance.
Via
InvestorPlace
BBIO Stock Earnings: BridgeBio Pharma Beats EPS, Beats Revenue for Q1 2024
May 02, 2024
BBIO stock results show that BridgeBio Pharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
What's Going On With BridgeBio Pharma Stock On Monday?
March 04, 2024
BridgeBio Pharma partners with Bayer on acoramidis for ATTR-CM in Europe. $310 million deal, FDA application accepted.
Via
Benzinga
Exposures
Product Safety
BridgeBio, A Top 3% Biotech, Just Snagged A $310 Million Deal; Will Shares Break Out?
March 04, 2024
BridgeBio will receive a tiered royalty on sales that begins at the low-30% range.
Via
Investor's Business Daily
Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday
February 15, 2024
U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Wednesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
3 Groundbreaking Biotech Stocks to Invest in Now
January 29, 2024
These are several biotech companies for investors seeking unique opportunities for great returns within the industry.
Via
InvestorPlace
7 Exciting Stocks Poised for Explosive Growth in Key Sectors
January 22, 2024
These stocks to buy for growth already have a strong growth story. If they reach their potential investors could see some dynamic returns.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.